GH1 and Hypoglycemia: Although lonapegsomatropin is approved for PGHD down to 1 year of age and somatrogon is approved for PGHD down to 3 years of age, children with severe GHD associated with hypoglycemia may not be good candidates for LAGH products since they may be at increased risk of hypoglycemia at trough GH levels occurring in the day or two prior to each injection.